CN116685314A - 用于预防或减轻对用于帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺（美多培坦） - Google Patents

用于预防或减轻对用于帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺（美多培坦） Download PDF

Info

Publication number
CN116685314A
CN116685314A CN202180089407.4A CN202180089407A CN116685314A CN 116685314 A CN116685314 A CN 116685314A CN 202180089407 A CN202180089407 A CN 202180089407A CN 116685314 A CN116685314 A CN 116685314A
Authority
CN
China
Prior art keywords
compound
formula
parkinson
disease
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180089407.4A
Other languages
English (en)
Chinese (zh)
Inventor
沃特斯 S·霍尔姆
J·M·泰德罗夫
P·斯文宁森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ireland 790 Corp
NTG Nordic Transport Group AS
Original Assignee
Ireland 790 Corp
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ireland 790 Corp, Neurosearch AS filed Critical Ireland 790 Corp
Publication of CN116685314A publication Critical patent/CN116685314A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180089407.4A 2020-11-10 2021-11-09 用于预防或减轻对用于帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺（美多培坦） Pending CN116685314A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206645 2020-11-10
EP20206645.2 2020-11-10
PCT/EP2021/081162 WO2022101227A1 (en) 2020-11-10 2021-11-09 [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias

Publications (1)

Publication Number Publication Date
CN116685314A true CN116685314A (zh) 2023-09-01

Family

ID=73288427

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180089407.4A Pending CN116685314A (zh) 2020-11-10 2021-11-09 用于预防或减轻对用于帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺（美多培坦）

Country Status (10)

Country Link
US (2) US20220168242A1 (https=)
EP (1) EP4243801A1 (https=)
JP (1) JP2023548429A (https=)
KR (1) KR20230106659A (https=)
CN (1) CN116685314A (https=)
AR (1) AR124036A1 (https=)
AU (1) AU2021378472A1 (https=)
CA (1) CA3198266A1 (https=)
TW (1) TW202233169A (https=)
WO (1) WO2022101227A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024062344A1 (en) * 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347517A (zh) * 2010-08-11 2013-10-09 费城健康及教育公司 治疗帕金森病中运动障碍的新型d3 多巴胺受体激动剂
CN105407879A (zh) * 2012-06-11 2016-03-16 赛科基因股份有限公司 与帕金森病治疗相关的副作用的治疗
CN107660147A (zh) * 2015-05-26 2018-02-02 抗菌技术生物技术研究与发展股份有限公司 用于治疗帕金森病和相关障碍的组合物
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080036957A (ko) 2005-06-23 2008-04-29 아스트라제네카 아베 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체
EP2699543B1 (en) 2011-04-19 2016-03-02 Integrative Research Laboratories Sweden AB Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
FI3976581T3 (fi) * 2019-05-24 2024-01-31 Irl 790 Ab [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347517A (zh) * 2010-08-11 2013-10-09 费城健康及教育公司 治疗帕金森病中运动障碍的新型d3 多巴胺受体激动剂
CN105407879A (zh) * 2012-06-11 2016-03-16 赛科基因股份有限公司 与帕金森病治疗相关的副作用的治疗
CN107660147A (zh) * 2015-05-26 2018-02-02 抗菌技术生物技术研究与发展股份有限公司 用于治疗帕金森病和相关障碍的组合物
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PER SVENNINGSSON ET AL.: ""Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia-a phase 1b trial"", 《NPJ PARKINSON’S DISEASE》, vol. 4, no. 35, 6 December 2018 (2018-12-06), pages 1 - 5 *

Also Published As

Publication number Publication date
AR124036A1 (es) 2023-02-08
CA3198266A1 (en) 2022-05-19
AU2021378472A1 (en) 2023-06-15
TW202233169A (zh) 2022-09-01
US20220168242A1 (en) 2022-06-02
WO2022101227A1 (en) 2022-05-19
KR20230106659A (ko) 2023-07-13
JP2023548429A (ja) 2023-11-16
US20240148674A1 (en) 2024-05-09
EP4243801A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
US20240148674A1 (en) Pharmaceutically acceptable salts of mesdopetam and uses thereof
CN113853369B (zh) [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途
TW520366B (en) Arylpiperazines having activity at the serotonin 1A receptor
CN101784273A (zh) (2s,3r)-n-(2-((3-吡啶基)甲基)-1-氮杂双环[2.2.2]辛-3-基)苯并呋喃-2-甲酰胺、其新的盐形式和用法
TW202334116A (zh) 一種取代的苯丙酸衍生物及其用途
CA2352324A1 (en) Derivatives of (-)-venlafaxine and methods of preparing and using the same
TW202400571A (zh) Ｒ－ｍｄｍａ晶體形式
HK40092836A (zh) 用於预防或减轻对用於帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺(美多培坦)
TWI376373B (en) Crystalline base of a pharmaceutical compound
CN120583945A (zh) 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
JPH03170428A (ja) 精神疾患治療剤
US20120157477A1 (en) Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
HK40063249B (zh) [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途
CN116178368A (zh) 一种甲状腺激素受体激动剂及其制备方法和应用
HK40063249A (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
JPWO2010032731A1 (ja) 結晶態様のベンゾイミダゾール化合物又はその塩
JP2026508826A (ja) 抗うつ化合物の塩、その製造方法、それを含む医薬組成物およびその用途
EA047399B1 (ru) Фармацевтически приемлемые соли [2-(3-фтор-5-метансульфонилфенокси)этил](пропил)амина и их применение
WO2022072620A1 (en) Methods of treating fibromyalgia with neuroactive steroids
US20150313891A1 (en) Neuronal nicotinic agonists and methods of use
HK1186469A (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092836

Country of ref document: HK